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Pulmonary BALT Lymphoma Successfully Treated with Eight 
Cycles Weekly Rituximab: Report of First Case and F-18 FDG 
PET/CT Images 
Extra marginal-zone lymphomas of the lung is a very rare tumor and it originates from 
bronchial-associated lymphoid tissue. A 68-yr-old woman presented with productive 
cough and dyspnea. A thorax computed tomography scan showed a 9 × 10 cm in size 
mass in the left lung and pleural effusion in the lower lobe of left lung. Positron emission 
tomography/computed tomography (PET/CT) revealed intense uptake foci at the upper and 
middle sites of left lung and slight uptake foci at the mediastinal lymph nodes which 
showed malignant involvement. After bronchoscopic biopsy, the diagnosis of pulmonary 
bronchial-associated lymphoid tissue (BALT) lymphoma was confirmed. At the end of the 
eight cycles weekly rituximab treatment, complete response was obtained by PET/CT 
findings. It is concluded that extended rituximab schedule is more effective and it would 
be beneficial to investigate the use of PET/CT in the diagnosis and evaluating of the 
treatment response of pulmonary BALT lymphoma.
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INTRODUCTION
Marginal-zone lymphomas (MZLs) comprise the mucosa-asso-
ciated lymphoid tissue (MALT) type (extranodal marginal-zone 
lymphoma [EMZL]), the nodal marginal-zone B-cell lympho-
ma and the splenic MZL. It is a distinc clinico-pathologic entity 
that usually follows an indolent course (1, 2). MALT lymphomas 
most commonly arise from gastrointestinal tract, however, they 
have been described in a wide variety of extranodal sites of the 
body including salivary glands, orbit and ocular adnexae, lung, 
skin, thyroid, breast, liver, kidney, bladder and prostate (3, 4). 
Pulmonary non-Hodgkin’s lymphoma (NHL) is very rare tumor, 
comprise only 0.5% of all pulmonary malignancies, more than 
two-thirds of all NHL of the lung, moreover, it is a rare entity and 
accounts for less than 1% of all lymphomas (5). EMZL of the lungs 
originates from bronchial-associated lymphoid tissue (BALT), 
which is histologically different from true intrapulmonary lymph-
node (6). While there is recognised association with helicobacter 
pylori infection in gastric MALT lymphomas, no certain agents 
have been identified that related with pulmonary MALT lym-
phoma. Previously it showed that chronic antigenic stimulation 
from smoking and some autoimmune diseases could play a role 
as trigger for the pulmonary MALT lymphomas (5). 
  Recommended treatment options include complete surgical 
excision, surgery followed by radiotherapy or chemotherapy 
alone but, the optimal therapy remains unclear (7-9). An alter-
native to cytotoxic chemotherapy is the use of rituximab because 
pulmonary MALT lymphoma cells typically expresses the CD 
20 antigen. Recently, we reported that a case of BALT lympho-
ma successfully treated with six cycles single agent rituximab 
therapy (10). We describe here first case of pulmonary MALT 
lymphoma who had obtained complete response after extend-
ed, eight cycles rituximab treatment.
CASE DESCRIPTION
A 68-yr-old woman was admitted to our hospital in January 2009, 
with six month history of productive cough and dyspnea for six 
months in January 2009. She had a history of hypertension for 8 
yr and was treated with amlodipine, 5 mg/day, p.o. She had nev-
er smoked. Her family history was non-contributory. On physi-
cal examination, lung auscultation revealed decreased breath 
sounds, coarse crepitations on the left lower lung site. There 
were no lympadenomegaly and organomegaly. 
  Initial laboratory results were as follows: urea 20 mg/dL, cre-
atinine 0.66 mg/dL, LDH 500 U/L (N:210-480), white blood cell 
(WBC) 6,500/μL, platelets 210,000/μL, hematocrit 41.7%, MCV 
91.4 fL. Other laboratory values were within normal limits. Her Bilici A, et al.  •  BALT Lymphoma and Extended Rituximab
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chest radiography showed non-homogen increased density on 
the left lower site. A thorax CT scan revealed a 9 × 10 cm in size 
mass in the left lung and consolidation including air broncho-
gram and pleural effusion in the lower lobe of left lung. Fluoro-
deoxyglucose (FDG) PET/CT revealed intense uptake foci at 
the upper and middle sites of left lung and slight uptake foci at 
the mediastinal lymph nodes which showed malignant involve-
ment (Fig. 1A). Thereafter, transbronchial biopsy was performed. 
Histopathological examination of biopsy specimen revealed a 
diffuse dense lymphocytic infiltrate composed of small mature 
lymphocytes with irregular nuclei. There was no evidence of 
large cell lymphoma. Immunohystochemical analysis showed 
that CD 20 (+), CD 43 focal (+), bcl 2 (+), CD 3 (–), CD 5 (–), CD 
10 (–), bcl 6 (–). The diagnosis of EMZL (pulmonary) of MALT 
was made by these findings. HIV and hepatitis C serology were 
negative and she had no underlying autoimmune disease. No 
pathological findings were detected in bone marrow biopsy.
  After the informed written consent was obtained, she was 
treated with the anti-CD 20 antibody rituximab, weekly iintra-
venous infusions of at a dose of 375 mg/m
2 with diagnosed clin-
ical stage IE pulmonary MALT lymphoma. After six courses of 
rituximab, the mass localized in the left lung was partially reg-
gressed (Fig. 1B). Complete response was achieved after com-
pletion of eight cycles of chemotherapy (Fig. 1C). No side effect 
was observed associated with rituximab. She had no specific 
symptom and was remained in the remission, during a follow-
up of 21 months. 
DISCUSSION
Primary non-Hodgkin’s lymphoma of the lung is a rare entity 
and although the prognosis of BALT lymphomas is favorable 
with 5-yr survival rates of over 85% and median survival of over 
10 yr in the largest reported series, clinical features, prognostic 
factors, and patient management have not been clearly defined 
(11). Treatment options of BALT lymphoma range from obser-
vation only to surgical resection alone or in combination with 
chemotherapy and radiotherapy but, the optimal therapy re-
mains controversial in the absence of any prospective studies 
(7-9). Watchful waiting for asymptomatic patients with surgi-
cally unresectable disease, or single-agent chemotherapy are 
reasonable options. In addition, combination chemotherapy 
may be considered in symptomatic patients with bulky or dis-
seminated disease. Various chemotherapeutic regimens with-
out surgical resection have been used and reported with differ-
ent outcome. Patients with unifocal disease may be often un-
dergo surgery at the first diagnosis, whereas in patients with mul-
tifocal disease there are two choices: watchful waiting strategy 
or chemotherapy ± antibody treatment (1). 
  Rituximab is a chimeric human/mouse anti-CD 20 mono-
clonal antibody that has emerged in recent years as an effective 
therapy for NHL and other B-cell malignancies. It has been ap-
proved for use in combination with CHOP chemotherapy regi-
men for the treatment of aggressive NHL (12). In the lack of pro-
pectively collected data, the therapeutic role of rituximab is un-
clear. Nevertheless, as BALT lymphoma cells express CD 20 an-
tigen, therefore, its use may be considered, alone or in comabi-
nation with other therapy. 
  In a study performed by Conconi et al. (13), they reported 
first phase-II study of rituximab in 34 patients with extranodal 
MALT lymphomas. Four patients with lung MALT lymphomas 
have included in this study, but the clinical response to ritux-
imab for these patients has not been clearly reported in this pa-
per. The authors indicated that the overall response rate (ORR) 
was 73% with median response duration 10.5 months. There 
was the high relaps rate (36%) in Conconi’s series and it showed 
that the 4-weekly-cycles regimen used may not represent the 
best schedule for administering rituximab in MALT lymphoma. 
However, previous studies reported that increasing evidence has 
already been provided in other lymphoma subtypes that higher 
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Fig. 1. Images by PET/CT scanning. (A) Diffuse hypermetabolic involvement (standard uptake value [SUV]:7.2) at the upper and middle site of the left lung and mild uptake foci 
at the mediastinal lymph nodes (SUV:3.4) which was compatible with malignancy. (B) Partial response after the sixth cycles rituximab. (C) Complete remission after eight cycles 
of rituximab medication.Bilici A, et al.  •  BALT Lymphoma and Extended Rituximab
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doses, maintenance treatment, and combination with conven-
tional chemotherapy may all be of benefit (14, 15). 
  The efficacy of rituximab in BALT lymphomas has been re-
ported (10, 16-19). In the English Medical literature, eight pati-
ents with BALTOMA who received single agent rituximab ther-
apy have been previously reported. In two of seven patients, it 
reported that CR was achieved with 4 and six cycles of rituximab, 
respectively (10, 18). Seker et al. (10) reported first case with BALT 
lymphoma treated with six cycles, weekly rituximab who had 
obtained CR, while all cases received four cycles of weekly ritux-
imab. In our case, partial response was obtained after four and 
six cycles weekly rituximab chemotherapy. Therefore, two ad-
ditional cycles were administered and pulmonary mass was re-
gressed completely. In previous reports if additional two or four 
cycles rituximab could be administered in patients with PR, CR 
might be achieved as our patient. To our knowledge, extended 
treatment with weekly doses rituximab is more better effective 
and safety as previous reports (15, 20). 
  This report constitutes the first case of BALT lymphoma suc-
cessfully treated with eight cycles, weekly rituximab in the liter-
ature. Also our case is noteworthy because of pre and after treat-
ment PET/CT images. We demonstrated that extended ritux-
imab schedules may result in increased efficacy in BALT lym-
phoma. On the other hand, the place and the duration of treat-
ment or schedules of rituximab need to be investigated by pro-
spective studies including a large sample size in the future.
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